Evidence mapPaperPMID 37653558Full record

ReviewDiabetology & metabolic syndrome2023

Antidepressants and type 2 diabetes: highways to knowns and unknowns.

Nahi Sabih Alruwaili, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Ali K Albuhadily, Amany E Ragab, Ahmad Awad Alenazi, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batiha

Open access · goldAbstract readReview
In one paragraph

Review in Diabetology & metabolic syndrome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Nahi Sabih AlruwailiEradah Complex of Mental Health -Northern Border Region, Ministry of Health, Al Bahah, Saudi Arabia.
Hayder M Al-KuraishyDepartment of Clinical pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Ali I Al-GareebDepartment of Clinical pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Ali K AlbuhadilyDepartment of Clinical pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Amany E RagabDepartment of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta, Egypt. amany.ragab@pharm.tanta.edu.eg.ORCID http://orcid.org/0000-0001-8276-5397
Ahmad Awad AlenaziNational guard health affairs, Riyadh, Saudi Arabia.
Athanasios AlexiouDepartment of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, NSW, 2770, Australia.
Marios PapadakisDepartment of Surgery II, University Hospital Witten-Herdecke, Wuppertal, 42283, Germany. marios_papadakis@yahoo.gr.
Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, AlBeheira, 22511, Egypt.
Mustansiriyah University · IQDamanhour University · EGMinistry of Health · SANational Guard Health Affairs · SATanta University · EGWitten/Herdecke University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes (T2D) is a metabolic disease caused by the development of insulin resistance (IR), relative insulin deficiency, and hyperglycemia. Hyperglycemia-induced neurochemical dysregulation activates the progression of depression in T2D patients. Therefore, management of depression by antidepressant agents improves glucose homeostasis and insulin sensitivity. However, prolong use of antidepressant drugs may increase the risk for the development of T2D. However, there is strong controversy concerning the use of antidepressant drugs in T2D. Therefore, this review try to elucidate the potential effects of antidepressant drugs in T2D regarding their detrimental and beneficial effects.

Indexed as

AntidepressantsDepressionType 2 diabetes

Identifiers

PMID37653558
PMCPMC10470155
OpenAlexW4386329364

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.